Creatine’s Double-Edged Cancer Twist

Woman in sportswear drinking a smoothie in a kitchen — Photo: eldar nurkovic / Shutterstock

A supplement found in nearly every gym bag in America might also be quietly fighting cancer cells in a lab dish, according to new research out of the University of California, Los Angeles (UCLA).

Quick Take

UCLA researchers found creatine boosted dendritic cells, immune cells that help spot and attack tumors, in mice and in human cells.
The same lab previously showed creatine powers killer T cells, another key soldier in the body’s cancer-fighting army.
A separate 2026 study found high-dose creatine raised metastasis risk in mice and made human blood platelets more reactive.
Scientists stress the findings are preclinical, meaning actual cancer patients haven’t been studied closely enough to draw firm conclusions.

What The New Dendritic Cell Study Found

Researchers published a study in the journal iScience showing creatine supplementation activated dendritic cells in mice and slowed tumor growth in a melanoma model. Dendritic cells act like scouts for the immune system. They find threats and alert other cells to attack. The team also tested human monocyte-derived dendritic cells in the lab and saw the same activation boost, suggesting the effect isn’t limited to mice.

Mice in the study received daily creatine injections, and scientists tracked both tumor size and the number of immune cells that made their way into the tumors. This builds on earlier UCLA work showing creatine also fuels CD8 T cells, the immune system’s frontline killers, giving them more energy to fight tumors in multiple mouse cancer models.

A Decade Of UCLA Research Points The Same Direction

This isn’t UCLA’s first finding on creatine and cancer. Years earlier, the same lab discovered creatine works like a molecular battery, storing and delivering energy that powers T cells during their fight against tumors. That early work laid the foundation for today’s immunotherapy research, and UCLA has since filed patent disclosures around using creatine to boost immune treatments for disease.

A systematic review of preclinical studies backed up the pattern, noting that creatine supplementation appears to help immune checkpoint inhibitor therapy, a common cancer treatment, work better by supporting T cell metabolism. The reviewers were careful to note this evidence comes from animal and lab models, not large human trials, so the real-world payoff for patients remains unproven.

A Competing Study Raises A Different Flag

Not every recent finding points the same direction. A study published in Nature Communications reported that creatine supplementation promoted tumor metastasis in mice through a signaling pathway involving blood-forming cells called megakaryocytes. The researchers also gave 11 healthy volunteers 20 grams of creatine daily for two weeks and found their blood platelets became more reactive, a change linked to higher clotting and metastasis risk in the mouse data.

Supplement industry analysts pushed back on how the study’s headline was covered, noting the human platelet findings didn’t involve any cancer patients and no human subject developed cancer or metastasis during the trial. Grok’s summary of the paper on social media captured the same detail, pointing out the dramatic title outpaced what the actual 11-person human arm demonstrated.

Why Mouse Results Rarely Translate Cleanly To Patients

Preclinical cancer research has a rough track record of carrying over into real treatments. Roughly nine out of ten drug candidates that look promising in early testing fail once they reach human clinical trials, largely because animal models don’t fully capture how human tumors behave or respond to treatment. That statistic isn’t specific to creatine, but it explains why a mouse finding, good or bad, shouldn’t be mistaken for a verdict on human health.

Clinical evidence in actual cancer patients remains thin on both sides of this debate. One trial of 263 patients with incurable disease tested creatine against a placebo and found little measurable benefit for most outcomes tracked. A broader review of the existing human and animal literature concluded that creatine’s effects on cancer patients remain uncertain, and that larger, longer human studies are needed before anyone draws solid conclusions.

For now, creatine sits in an unusual spot. Decades of sports science back its safety and muscle benefits for healthy adults. Cancer research is a different story still being written, with legitimate findings pointing in two directions at once. Patients considering creatine during cancer treatment should talk with their oncologist, since the supplement’s effects may depend heavily on cancer type, dose, and individual health factors not yet fully studied.